Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/follow-up-in-aggressive-lymphomas-h36mAzGxSR
References (10)
-
M. Pfreundschuh, J. Schubert, M. Ziepert, R. Schmits, M. Mohren, E. Lengfelder, M. Reiser, C. Nickenig, M. Clemens, N. Peter, C. Bokemeyer, H. Eimermacher, A. Ho, M. Hoffmann, R. Mertelsmann, L. Trümper, L. Balleisen, R. Liersch, B. Metzner, F. Hartmann, B. Glass, V. Poeschel, N. Schmitz, C. Ruebe, A. Feller, M. Loeffler (2008)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).The Lancet. Oncology, 9 2
-
P. Armand, A. Nagler, Edie Weller, Steven Devine, D. Avigan, Yi-Bin Chen, Mark Kaminski, H. Holland, Jane Winter, James Mason, J. Fay, D. Rizzieri, C. Hosing, Edward Ball, J. Uberti, H. Lazarus, Markus Mapara, Stephanie Gregory, J. Timmerman, David Andorsky, Reuven Or, Edmund Waller, R. Rotem‐Yehudar, Leo Gordon (2013)
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 33
-
P. Stiff, J. Unger, J. Cook, L. Constine, S. Couban, D. Stewart, T. Shea, P. Porcu, J. Winter, B. Kahl, T. Miller, R. Tubbs, D. Marcellus, J. Friedberg, K. Barton, G. Mills, M. LeBlanc, L. Rimsza, S. Forman, R. Fisher (2013)
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.The New England journal of medicine, 369 18
-
D. Cunningham, E. Hawkes, A. Jack, W. Qian, Paul Smith, P. Mouncey, C. Pocock, K. Ardeshna, J. Radford, A. McMillan, J. Davies, D. Turner, A. Kruger, P. Johnson, J. Gambell, D. Linch (2013)
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cyclesThe Lancet, 381
-
Zheng Zhou, L. Sehn, A. Rademaker, L. Gordon, A. LaCasce, Allison Crosby‐Thompson, A. Vanderplas, A. Zelenetz, G. Abel, M. Rodriguez, A. Nademanee, M. Kaminski, M. Czuczman, M. Millenson, J. Niland, R. Gascoyne, J. Connors, J. Friedberg, J. Winter (2014)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.Blood, 123 6
-
E. Jacobsen (2013)
Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 33
-
N. Schmitz, M. Nickelsen, M. Ziepert, M. Haenel, P. Borchmann, C. Schmidt, A. Viardot, M. Bentz, N. Peter, G. Ehninger, G. Doelken, C. Ruebe, L. Truemper, A. Rosenwald, M. Pfreundschuh, M. Loeffler, B. Glass (2012)
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).The Lancet. Oncology, 13 12
-
C. Récher, B. Coiffier, C. Haioun, T. Molina, C. Fermé, O. Casasnovas, C. Thieblemont, A. Bosly, G. Laurent, F. Morschhauser, H. Ghesquières, F. Jardin, S. Bologna, C. Fruchart, B. Corront, J. Gabarre, C. Bonnet, M. Janvier, D. Canioni, J. Jais, G. Salles, H. Tilly (2011)
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trialThe Lancet, 378
-
M. Pfreundschuh, L. Trümper, A. Osterborg, R. Pettengell, M. Trněný, K. Imrie, D. Ma, D. Gill, J. Walewski, P. Zinzani, R. Stahel, S. Kvaløy, O. Shpilberg, U. Jaeger, M. Hansen, T. Lehtinen, A. López-Guillermo, C. Corrado, A. Scheliga, N. Milpied, M. Mendila, M. Rashford, E. Kuhnt, M. Loeffler (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.The Lancet. Oncology, 7 5
-
(2012)
R - CHOP 14 compared to R - CHOP 21 in elderly patients with diffuse large B - cell lymphoma ( DLBCL ) : final analysis of the LNH 03 - 6 B GELA study
- Publisher
- Springer Journals
- Copyright
- Copyright © 2014 by Springer-Verlag Wien
- Subject
- Medicine & Public Health; Oncology; Medicine/Public Health, general
- ISSN
- 1865-5041
- eISSN
- 1865-5076
- DOI
- 10.1007/s12254-014-0141-0
- Publisher site
- See Article on Publisher Site
Abstract
A number of important contributions to the clinical knowledge of aggressive B-cell lymphoma were published over the past year. Among potential practice-changing studies—or those preventing unjustified change, were studies on improved risk classification, dose-dense immunochemotherapy, early autologous stem-cell transplantation, and the first clinical report on the use of immune checkpoint blockade to improve outcome of high-dose therapy.
Journal
memo - Magazine of European Medical Oncology – Springer Journals
Published: May 21, 2014